摘要
目的分析乙型肝炎肝硬化失代偿期患者应用血府逐瘀汤加减治疗的临床效果。方法择取88例确诊为乙型肝炎肝硬化且疾病处于失代偿期患者为观察对象,依据随机原则分为对照组和观察组,各44例。对照组给予常规治疗,观察组在对照组基础上加血府逐瘀汤加减治疗。对比两组肝纤维化指标、炎性因子水平,生活质量评分及不良反应发生情况。结果治疗后,观察组层粘连蛋白(LN)、透明质酸(HA)、Ⅳ型胶原(Ⅳ-C)、Ⅲ型前胶原肽(PⅢP)分别为(114.87±18.01)、(83.28±15.39)、(89.95±20.54)、(93.93±18.12)μg/L,低于对照组的(146.58±20.92)、(133.64±18.63)、(106.28±20.21)、(115.14±18.25)μg/L(P<0.05)。治疗后,观察组白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)分别为(42.63±6.13)ng/L、(37.14±7.61)fmol/ml、(5.32±1.03)mg/L,均低于对照组的(55.34±7.63)ng/L、(55.03±8.35)fmol/ml、(8.74±2.14)mg/L(P<0.05)。治疗后,观察组心理功能、生理功能、躯体功能、社会职能评分分别为(78.74±3.68)、(76.07±4.23)、(77.61±3.77)、(74.47±4.26)分,均高于对照组的(72.23±3.17)、(71.29±4.38)、(70.33±3.69)、(72.06±4.37)分(P<0.05)。治疗后,两组不良反应发生率对比无明显差异(P>0.05)。结论乙型肝炎肝硬化失代偿期患者在常规治疗基础上增加血府逐瘀汤加减治疗有助于提升患者临床疗效,促进肝纤维化指标、炎性因子水平的优化,全面提升患者的生活质量。
Objective To analyze the clinical effect of modified Xuefu Zhuyu Decoction on liver fibrosis markers and inflammatory factors in patients with decompensated hepatitis B cirrhosis.Methods 88 patients diagnosed with hepatitis B cirrhosis and in the decompensated stage of the disease were selected as observation subjects.They were divided into control group and observation group according to the principle of random grouping,each with 44 patients.The control group received conventional treatment,and the observation group received modified Xuefu Zhuyu Decoction on the basis of the control group.The liver fibrosis markers,inflammatory factor level,quality of life score,and occurrence of adverse reactions were compared between the two groups.Results After treatment,the laminin(LN),hyaluronic acid(HA),typeⅣcollagen(Ⅳ-C)and typeⅢprocollagen peptide(PⅢP)in the observation group were(114.87±18.01),(83.28±15.39),(89.95±20.54)and(93.93±18.12)μg/L,which were lower than(146.58±20.92),(133.64±18.63),(106.28±20.21)and(115.14±18.25)μg/L in the control group(P<0.05).After treatment,the interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and hypersensitive C-reactive protein(hs-CRP)in the observation group were(42.63±6.13)ng/L,(37.14±7.61)fmol/ml and(5.32±1.03)mg/L,which were lower than(55.34±7.63)ng/L,(55.03±8.35)fmol/ml and(8.74±2.14)mg/L in the control group(P<0.05).After treatment,the scores of psychological function,physical function,bodily function and social function in the observation group were(78.74±3.68),(76.07±4.23),(77.61±3.77)and(74.47±4.26)points,which were higher than(72.23±3.17),(71.29±4.38),(70.33±3.69)and(72.06±4.37)points in the control group(P<0.05).After treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Modified Xuefu Zhuyu Decoction on the basis of conventional treatment for the treatment of patients with decompensated hepatitis B cirrhosis can help to improve the clinical efficacy,promote the optimization of liver fibrosis markers and inflammatory factors,and comprehensively improve the quality of life of patients.
作者
李杨
LI Yang(Tai'an Traditional Chinese Medicine Hospital,Tai'an 271000,China)
出处
《中国实用医药》
2025年第10期34-38,共5页
China Practical Medicine
关键词
乙型肝炎
肝硬化
失代偿期
血府逐瘀汤
肝纤维化指标
炎性因子
Hepatitis B
Cirrhosis
Decompensation
Xuefu Zhuyu Decoction
Liver fibrosis markers
Inflammatory factors
